It is currently Mon Apr 22, 2019 7:16 pm

Post new topic Reply to topic  [ 2 posts ] 
 Dr. Burzynski Cancer Is Serious Business 
Author Message
Site Admin
User avatar

Joined: Sun Mar 25, 2007 8:54 am
Posts: 4866
Location: Canada
Post Dr. Burzynski Cancer Is Serious Business
I am simply sharing this information, please consult your Doctor before trying anything like this

Cancer Is Serious Business

This is a must watch documentary for anyone that has any form of cancer. or knows anyone with this Dr Burzynski's Antineoplaston therapy will most likely cure....including brain tumors!

From Wikipedia, the free encyclopedia

Here is his Clinic

Image Please Obey the Golden Rules viewtopic.php?f=31&t=3563&p=40912#p40912

Mon Oct 31, 2011 9:07 am
Profile WWW
Site Admin
User avatar

Joined: Sun Oct 11, 2009 8:59 am
Posts: 6532
Location: Friendswood, TX
Post Re: Dr. Burzynski Cancer Is Serious Business
Yeah, this guy is from my dear ole home town.

Here's some info from the American Cancer Society:

What does it involve?

Antineoplastons are given orally or by injection into a vein. The duration of treatment usually ranges from eight to twelve months. A year of treatment can cost from $30,000 to $60,000, depending on the type of treatment, number of consultations, and the need for surgery to implant a catheter for drug delivery.

Antineoplaston therapy was developed by Stanislaw Burzynski, MD, PhD. Initial treatments are given over the course of one to three weeks at a clinic in Houston, founded by Dr. Burzynski. (Other U.S. centers are participating in studies to evaluate this treatment, as well as some centers in other countries.) Further treatments may be given "at home," but require monthly visits to a doctor, either at the Houston clinic or elsewhere with one of Dr. Burzynski's research colleagues. In the past, many of the patients who received antineoplaston treatment also were treated with surgery, radiation, chemotherapy, or combinations of these standard treatments at other centers, and some received chemotherapy prescribed by Dr. Burzynski. Currently, antineoplaston treatment is available in the United States only through participation in clinical trials led by Dr. Burzynski and his colleagues. To be eligible for these clinical studies, patients must have cancer that is growing despite conventional treatments. Patients cannot receive conventional anticancer treatments while they are participating in these antineoplaston studies. :nono


During the 1980s, the United States Congressional Office of Technology Assessment (OTA) reviewed medical journal articles describing cases of cancer patients whom Dr. Burzynski had treated with antineoplaston therapy. Its report, published in 1990, concludes that, "Despite a substantial number of preliminary clinical studies published by Burzynski and his associates describing outcomes among the patients he treated with Antineoplastons and an attempt at a 'best case' review, there is still a lack of valid information to judge whether this treatment is likely to be beneficial to cancer patients." The OTA report criticized Burzynski's research process and noted that his definitions of advanced cancer and of complete and partial cancer remission were not used in accordance with generally accepted definitions. One example they pointed to was a patient said to have had a complete remission after treatment with antineoplastons. The report concluded, however, that this claim was inappropriate because the cancer had been removed by surgery before the antineoplaston treatment was started.

In 1982, consultants to the Ontario (Canada) Ministry of Health visited Burzynski's clinic and reviewed records of twelve patients selected by Burzynski from among the thousands he had treated. According to the OTA report, the Canadian doctors "found no examples of objective response to Antineoplastons." In 1985, the Canadian Bureau of Prescription Drugs examined the records of Canadian doctors who had treated patients at Dr. Burzynski's clinic in Houston. Of 36 patients, 32 had died without showing signs of improvement. Of the remaining 4, one patient died after slight improvement, while one patient died after stabilizing for a year. The 2 remaining patients had widespread cancer.

In 1991, the National Cancer Institute (NCI) reviewed several 'best cases' (involving patients with brain tumors) chosen by Burzynski. According to a 1992 article in the Journal of the National Cancer Institute, "two NCI extramural investigators independently reviewed the case histories of some patients treated with antineoplastons. At the investigators' recommendation, the NCI examined the case histories, pathology slides, and imaging studies from seven patients with primary brain tumors ….[T]he site visit team and, subsequently, the [NCI] Division of Cancer Treatment's Decision Network Committee believed that evidence of possible antitumor effect was demonstrated." NCI concluded that these results warranted further investigation through clinical trials at other medical centers. But because of disagreement between NCI researchers and Burzynski, the clinical trials were terminated in 1995. By 1999, the researchers concluded that only 6 of the 9 patients treated in that study could be evaluated according to the study's initial requirements. None of the 6 showed evidence of tumor shrinkage. The researchers noted, however, that the small number of patients participating limited their ability to say with confidence that antineoplaston treatment had no benefit. Side effects of antineoplaston treatment included temporary sleepiness and confusion, and worsening of epilepsy (seizures) in patients who already had that problem (as a result of the tumors).

Dr. Burzynski currently has permission from the FDA to conduct clinical trials of antineoplaston therapy at his clinic. The NCI and researchers at several cancer centers are also conducting laboratory experiments on the peptides involved in antineoplaston therapy.

While many articles have been published and dozens of clinical trials against many types of cancer have been ongoing at Dr. Burzynski's clinic for several years, there have not been any randomized controlled trials—the type of study that is required for new anticancer drugs to be approved by the FDA and recommended by conventional oncologists.

Although some proponents of antineoplaston therapy have suggested that the reviews of this treatment by conventional cancer specialists are biased by mistrust of alternative therapies, even some prominent figures in the field of alternative medicine have reservations about antineoplastons. According to Dr. Andrew Weil, "Over the years, Dr. Burzynski claims to have treated more than 8,000 patients, but his success rates are unknown. His Web site states only that he has helped 'many' people. If antineoplaston therapy works, we should have scientific studies showing what percentage of patients treated have survived and for how long, as well as evidence showing how Dr. Burzynski's method stacks up against conventional cancer treatment…. Until we have credible scientific evidence showing what antineoplastons are, how they act in the body, and what realistic expectations of treatment with them might be, I see no reason for any cancer patient to take this route."


Read more here:

The test of our progress is not whether we add more to the abundance of those who have much; it is whether we provide enough for those who have too little. - FDR

Mon Oct 31, 2011 8:25 pm
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

Who is online

Users browsing this forum: No registered users and 2 guests

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Jump to:  
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group.
Designed by Vjacheslav Trushkin for Free Forums/DivisionCore.